Invivyd said Q4 2025 net product revenue from PEMGARDA was USD 17.2 million, up 25% YoY and 31% QoQ. For FY 2025, PEMGARDA net product revenue was USD 53.4 million. The company reported a FY 2025 net loss of USD 52.5 million, or USD 0.30 per share, and ended 2025 with cash and cash equivalents of USD 226.7 million after raising over USD 200 million in 2H 2025. FY 2025 R&D expenses were USD 38.3 million and SG&A expenses were USD 66.9 million. On business updates, Invivyd said its DECLARATION Phase 3 pivotal trial of VYD2311 to prevent COVID is fully enrolled, with top-line data expected mid-2026; the FDA granted Fast Track designation for VYD2311 in December 2025. The trial’s IDMC recommended allowing enrollment of pregnant and breastfeeding women, removed contraception requirements for women of childbearing age, and said certain protocol-specified safety visits are no longer required. The company also said it received FDA advice on the LIBERTY Phase 3 trial comparing VYD2311 with mRNA COVID vaccines, and plans to initiate a Phase 2 trial of VYD2311 in Long COVID or COVID vaccine injury by mid-2026. Invivyd appointed Michael Mina as Chief Medical Officer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603050703PRIMZONEFULLFEED9666209) on March 05, 2026, and is solely responsible for the information contained therein.